MCM
ECYT

Matarin Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Matarin Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-39,307
Closed -$59K – 312
2017
Q2 		$59K Hold
39,307
– – 0.01% 275
2017
Q1 		$101K Buy
+39,307
New +$90.9K 0.01% 281

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Curi RMB Capital
Curi RMB Capital Chicago, Illinois $6.48B AUM 30.25% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Panagora Asset Management
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Matarin Capital Management's ECYT Position: Q3 2017 in Review

Matarin Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2017, closing a stake of 39,307 shares — an estimated $59K sold.

Matarin Capital Management first reported a position in ECYT in Q1 2017 and held it in 2 quarters. The position peaked at $101K in Q1 2017. 63 funds tracked by Wall St. Rank hold ECYT as of Q3 2017.

  • Matarin Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Matarin Capital Management sold 39,307 Endocyte, Inc. Common Stock shares in Q3 2017, an estimated $59K.
  • Matarin Capital Management first reported a position in Endocyte, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Matarin Capital Management's Endocyte, Inc. Common Stock position peaked at $101K in Q1 2017.
  • 63 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2017.

Based on Matarin Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.